Strata Critical Medical (SRTA) Cash & Current Investments (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Cash & Current Investments data on file, last reported at $58.8 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $58.8 million, down 51.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.8 million (down 51.01% YoY), and the FY2025 annual result was $61.2 million, down 50.95% from the prior year.
• Cash & Current Investments eased to $58.8 million in Q1 2026 per SRTA's latest filing, from $61.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $269.1 million in Q1 2022 and troughed at $53.4 million in Q3 2025.
• A 5-year average of $147.1 million and a median of $142.0 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 3482.16% in 2022, then tumbled 60.81% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $153.8 million in 2022, then fell by 9.37% to $139.4 million in 2023, then fell by 10.46% to $124.8 million in 2024, then tumbled by 50.95% to $61.2 million in 2025, then declined by 3.99% to $58.8 million in 2026.
• Business Quant data shows SRTA's Cash & Current Investments at $58.8 million in Q1 2026, $61.2 million in Q4 2025, and $53.4 million in Q3 2025.